This is Thomas Sullivan's Typepad Profile.
Join Typepad and start following Thomas Sullivan's activity
Join Now!
Already a member? Sign In
Thomas Sullivan
Columbia, Maryland
Former political consultant who founded Rockpointe, Inc. a bio-medical education company in 1995.
Interests: marketing, politics, baseball, cycling, medicine, university of florida sports., medical education, track and cross country,driving kids to various practices
Recent Activity
Image
Pharmaceutical and device manufacturers spent several years and millions of dollars developing systems and processes to properly track the reams of data required to comply with the Physician Payments Sunshine Act. Two weeks ago, many manufacturers had to read ProPublica... Continue reading
Posted 4 hours ago at Policy and Medicine
Image
Many physicians and other healthcare providers refer a high volume of patient specimens to third party clinical laboratories every day. The Office of the Inspector General (OIG) for the U.S. Department of Health and Human Services recently issued a Special... Continue reading
Posted 4 days ago at Policy and Medicine
Image
CMS still aiming to publish its data by September 30th. The Centers for Medicare and Medicaid Services (CMS) just emailed out new updates for physicians looking to access their payment data on Open Payments: Access to the Open Payments system... Continue reading
Posted 5 days ago at Policy and Medicine
Image
Physicians in all specialties have steadily adopted electronic health records (EHRs). However, as doctors have embraced technology for streamlining patient records, we have seen a marked uptick in data breaches by hackers who want access to the reams of information... Continue reading
Posted 5 days ago at Policy and Medicine
Image
On Tuesday, Pharmaceutical Research and Manufacturers of America (PhRMA) Assistant General Counsel, John Murphy, issued a statement regarding the announcement by the Centers for Medicare and Medicaid Services (CMS) to delay publication of a significant portion of data in the... Continue reading
Posted 5 days ago at Policy and Medicine
Image
Starting in 2016, European Federation of Pharmaceutical Industries and Associations (EFPIA) member companies will make public the details of payments and transfers of value made to healthcare professionals and healthcare organizations. EFPIA sets out the requirements for tracking and reporting... Continue reading
Posted 6 days ago at Policy and Medicine
Image
The EFPIA Disclosure Code requires all member companies of EFPIA, the European Federation of Pharmaceutical Industries and Associations, to disclose payments and other transfers of value made to healthcare practitioners and organizations. Like the Physician Payments Sunshine Act, the 33... Continue reading
Posted 7 days ago at Policy and Medicine
Image
After a 12-day delay in the Dispute Resolution process, it seems like some doctors were anxious to get into Open Payments and review their data: The American Medical Association (AMA) has been urging CMS to extend the dispute window and... Continue reading
Posted 7 days ago at Policy and Medicine
Image
The Accreditation Council for Continuing Medical Education (ACCME) has sent a letter to CMS urging them to reconsider their proposal to remove Section 403.904(g)(1), the CME exemption, from the Sunshine Act. The ACCME joins a long list of commenters who... Continue reading
Posted Aug 25, 2014 at Policy and Medicine
Image
As reported by The Hill, earlier this year, the Senate Appropriations Committee told the Food and Drug Administration (FDA) to reach out to stakeholders such as physicians, patients and pharmacists before releasing new guidances for compounding pharmacies. Under the 2013... Continue reading
Posted Aug 22, 2014 at Policy and Medicine
The Council of Medical Specialty Societies (CMSS), which represents forty-one societies with an aggregate membership of 750,000 U.S. physicians, recently submitted their comments to CMS regarding the proposal to eliminate the CME exemption from the Final Rule implementing the Sunshine... Continue reading
Posted Aug 21, 2014 at Policy and Medicine
Image
Yesterday, CMS addressed why many records have been deleted from Open Payments. As we wrote, many of the problems are tied to the system's reliance on the NPPES database. "Records submitted to Open Payments are considered invalid if: 1. The... Continue reading
Posted Aug 21, 2014 at Policy and Medicine
Image
This week, scores of executives from pharmaceutical and device companies gathered in Washington, DC for CBI’s Eighth Annual Transparency and Aggregate Spend Forum to gain new insights into Sunshine Act compliance. On Monday, most companies were talking about rumors of... Continue reading
Posted Aug 20, 2014 at Policy and Medicine
Image
As reported by the law firm Husch Blackwell, a recent D.C. Circuit court decision reaffirms that the attorney-client privilege applies with equal force to internal investigations today as it did 30 years ago. We often cover compliance stories on our... Continue reading
Posted Aug 20, 2014 at Policy and Medicine
Image
This article examines the shifting timeline for Open Payments registration, the dispute resolution process, and as of August 15, the dates for the public database. As the many announcements from the Centers for Medicare and Medicaid Services (CMS) over the... Continue reading
Posted Aug 19, 2014 at Policy and Medicine
Image
In just over a month, on September 30th, the Centers for Medicare and Medicaid Services (CMS) is scheduled to publish a searchable online database of manufacturers’ payments to physicians and teaching hospitals. Charles Ornstein of ProPublica reports that CMS will... Continue reading
Posted Aug 18, 2014 at Policy and Medicine
Image
Recently, the US Food and Drug Administration (FDA) released a new draft guidance document on the content and format of generic drug submissions using the common technical document (CTD). As reported, FDA's new draft guidance document, ANDA Submissions — Content... Continue reading
Posted Aug 18, 2014 at Policy and Medicine
Image
As an update on our continuing coverage of the Open Payments website and physician dispute resolution process, the Centers for Medicare and Medicaid Services has just officially announced that their website has re-opened and that CMS would indeed extend the... Continue reading
Posted Aug 15, 2014 at Policy and Medicine
Image
August 14, 2014: The Centers for Medicare and Medicaid Services (CMS) have fixed the technical problems that caused Open Payments to be offline since August 3, the Wall Street Journal reports. The dispute and resolution period for physicians and teaching... Continue reading
Posted Aug 15, 2014 at Policy and Medicine
Image
We have written previously about the "Meaningful Use" electronic health record (EHR) initiative, which is run by the Centers for Medicare & Medicaid Services (CMS). As a brief refresher: Under the 2009 Health Information Technology for Economic and Clinical Health... Continue reading
Posted Aug 15, 2014 at Policy and Medicine
Image
Since 2006, Celgene Corporation has earned $20.9 billion from the sales of two of its drugs—Thalomid and Revlimid. The drugs are used for patients suffering from multiple myeloma. This year, Celgene has posting amazing sales of Revlimid in particular—doctors are... Continue reading
Posted Aug 14, 2014 at Policy and Medicine
Image
Celgene's successful cancer drugs Thalomid and Revlimid are at the center of an antitrust action. On April 3rd, Mylan Pharmaceuticals Inc. filed an antitrust lawsuit against Celgene Corporation in the U.S. District Court of New Jersey, accusing Celgene of blocking... Continue reading
Posted Aug 14, 2014 at Policy and Medicine
Image
The European Medicines Agency (EMA) Management Board has been inching towards a policy on clinical trial transparency. Striking a compromise between opposing stakeholders, however, has proved challenging. The European Union's pharmaceutical regulator has been moving towards a policy since at... Continue reading
Posted Aug 13, 2014 at Policy and Medicine
Image
A recent article in Forbes argues that misplaced public distrust of the pharmaceutical industry could harm the research and development of important antibiotics. Entitled, "Pharma's Poor Reputation Doesn't Help in the Fight of Superbugs," the article examines the industry's reputation... Continue reading
Posted Aug 12, 2014 at Policy and Medicine
Image
"There is a striking absence of transparency and accountability in the GME financing system for producing the types of physicians the nation needs," states the Institute of Medicine's Committee on the Governance and Financing of Graduate Medical Education (GME). The... Continue reading
Posted Aug 12, 2014 at Policy and Medicine